The referenced media source is missing and needs to be re-embedded. Read more
By Kara Nyberg, PhD Posted: June 24, 2020 New findings from the TRACERx lung study underscore the value of using circulating tumor DNA (ctDNA) to predict NSCLC relapse postsurgery based […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 The phase II PASSION trial sought to explore the potential synergy between immunotherapy and antiangiogenic drug therapy previously observed in preclinical studies. […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold tumor immune microenvironment in […] Read more
The COVID-19 pandemic has created numerous challenges with the management of lung cancer, not the least of which is the initial diagnosis. The computer tomography scans, typically used in the […] Read more
Watch Recording IASLC faculty members from Europe, Asia and North America will discuss systemic therapies including chemotherapy, immunotherapy, and targeted therapy for advanced-stage lung cancer during the COVID-19 global pandemic. […] Read more
Watch Recording This webinar, “Impact of COVID-19 on Treatment of Lung Cancer Patients with Local or Locoregional Disease,” will be presented by IASLC surgical and radiation oncology experts. Faculty will […] Read more